1
|
Cocozza F, Névo N, Piovesana E, Lahaye X, Buchrieser J, Schwartz O, Manel N, Tkach M, Théry C, Martin‐Jaular L. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus. J Extracell Vesicles 2020; 10:e12050. [PMID: 33391636 PMCID: PMC7769856 DOI: 10.1002/jev2.12050] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 11/16/2020] [Accepted: 12/04/2020] [Indexed: 12/29/2022] Open
Abstract
SARS-CoV-2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 and subsequent priming by host TMPRSS2 allowing membrane fusion. Here, we produced extracellular vesicles (EVs) exposing ACE2 and demonstrate that ACE2-EVs are efficient decoys for SARS-CoV-2 S protein-containing lentivirus. Reduction of infectivity positively correlates with the level of ACE2, is much more efficient than with soluble ACE2 and further enhanced by the inclusion of TMPRSS2.
Collapse
Affiliation(s)
- Federico Cocozza
- INSERM U932Institut Curie Centre de RecherchePSL Research UniversityParisFrance
- Université de ParisParisFrance
| | - Nathalie Névo
- INSERM U932Institut Curie Centre de RecherchePSL Research UniversityParisFrance
| | - Ester Piovesana
- INSERM U932Institut Curie Centre de RecherchePSL Research UniversityParisFrance
- Université de ParisParisFrance
| | - Xavier Lahaye
- INSERM U932Institut Curie Centre de RecherchePSL Research UniversityParisFrance
| | - Julian Buchrieser
- Virus and Immunity UnitInstitut Pasteur and CNRS UMR 3569ParisFrance
| | - Olivier Schwartz
- Virus and Immunity UnitInstitut Pasteur and CNRS UMR 3569ParisFrance
| | - Nicolas Manel
- INSERM U932Institut Curie Centre de RecherchePSL Research UniversityParisFrance
| | - Mercedes Tkach
- INSERM U932Institut Curie Centre de RecherchePSL Research UniversityParisFrance
| | - Clotilde Théry
- INSERM U932Institut Curie Centre de RecherchePSL Research UniversityParisFrance
| | | |
Collapse
|
2
|
Protiere C, Arnold M, Fiorentino M, Fressard L, Lelièvre JD, Mimi M, Raffi F, Mora M, Meyer L, Sagaon‐Teyssier L, Zucman D, Préau M, Lambotte O, Spire B, Suzan‐Monti M. Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment. J Int AIDS Soc 2020; 23:e25443. [PMID: 32077248 PMCID: PMC7048214 DOI: 10.1002/jia2.25443] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Accepted: 12/04/2019] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION Despite the advent of HIV cure-related clinical trials (HCRCT) for people living with HIV (PLWH), the risks and uncertainty involved raise ethical issues. Although research has provided insights into the levers and barriers to PLWH and physicians' participation in these trials, no information exists about stakeholders' preferences for HCRCT attributes, about the different ways PLWH and physicians value future HCRCT, or about how personal characteristics affect these preferences. The results from the present study will inform researchers' decisions about the most suitable HCRCT strategies to implement, and help them ensure ethical recruitment and well-designed informed consent. METHODS Between October 2016 and March 2017, a discrete choice experiment was conducted among 195 virally controlled PLWH and 160 physicians from 24 French HIV centres. Profiles within each group, based on individual characteristics, were obtained using hierarchical clustering. Trade-offs between five HCRCT attributes (trial duration, consultation frequency, moderate (digestive disorders, flu-type syndrome, fatigue) and severe (allergy, infections, risk of cancer) side effects (SE), outcomes) and utilities associated with four HCRCT candidates (latency reactivation, immunotherapy, gene therapy and a combination of latency reactivation and immunotherapy), were estimated using a mixed logit model. RESULTS Apart from severe SE - the most decisive attribute in both groups - PLWH and physicians made different trade-offs between HCRCT attributes, the latter being more concerned about outcomes, the former about the burden of participation (consultation frequency and moderate SE). These different trades-offs resulted in differences in preferences regarding the four candidate HCRCT. PLWH significantly preferred immunotherapy, whereas physicians preferred immunotherapy and combined therapy. Despite the heterogeneity of characteristics within the PLWH and physician profiles, results show some homogeneity in trade-offs and utilities regarding HCRCT. CONCLUSIONS Severe SE, not outcomes, was the most decisive attribute determining future HCRCT participation. Particular attention should be paid to providing clear information, in particular on severe SE, to potential participants. Immunotherapy would appear to be the best HCRCT candidate for both PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former.
Collapse
Affiliation(s)
- Christel Protiere
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information MédicaleAix Marseille UnivMarseilleFrance
- ORS PACAObservatoire régional de la santé Provence‐Alpes‐Côte d'AzurMarseilleFrance
| | | | - Marion Fiorentino
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information MédicaleAix Marseille UnivMarseilleFrance
- ORS PACAObservatoire régional de la santé Provence‐Alpes‐Côte d'AzurMarseilleFrance
| | - Lisa Fressard
- ORS PACAObservatoire régional de la santé Provence‐Alpes‐Côte d'AzurMarseilleFrance
| | - Jean D Lelièvre
- INSERMCréteilFrance
- Faculté de médecineUniversité Paris EstCréteilFrance
- Vaccine Research InstituteCréteilFrance
| | - Mohamed Mimi
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information MédicaleAix Marseille UnivMarseilleFrance
- ORS PACAObservatoire régional de la santé Provence‐Alpes‐Côte d'AzurMarseilleFrance
| | - François Raffi
- Department of Infectious DiseasesHotel‐Dieu Hospital ‐ INSERM CIC 1413Nantes University HospitalNantesFrance
| | - Marion Mora
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information MédicaleAix Marseille UnivMarseilleFrance
- ORS PACAObservatoire régional de la santé Provence‐Alpes‐Côte d'AzurMarseilleFrance
| | - Laurence Meyer
- Département d'épidémiologie, INSERM, U1018Université Paris‐Sud 11AP‐HPHôpital de BicêtreLe Kremlin‐BicêtreFrance
| | - Luis Sagaon‐Teyssier
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information MédicaleAix Marseille UnivMarseilleFrance
- ORS PACAObservatoire régional de la santé Provence‐Alpes‐Côte d'AzurMarseilleFrance
| | - David Zucman
- Hôpital Foch, service de médecine interneSuresnesFrance
| | | | - Olivier Lambotte
- Assistance Publique ‐ Hôpitaux de ParisHôpital BicêtreService de Médecine Interne et Immunologie cliniqueLe Kremlin‐BicêtreFrance
- Immunology of Viral Infections and Autoimmune DiseasesINSERM, U1184Le Kremlin‐BicêtreFrance
- UMR 1184Université Paris SudLe Kremlin‐BicêtreFrance
- CEADSV/iMETIIDMITFontenay‐aux‐RosesFrance
| | - Bruno Spire
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information MédicaleAix Marseille UnivMarseilleFrance
- ORS PACAObservatoire régional de la santé Provence‐Alpes‐Côte d'AzurMarseilleFrance
| | - Marie Suzan‐Monti
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information MédicaleAix Marseille UnivMarseilleFrance
- ORS PACAObservatoire régional de la santé Provence‐Alpes‐Côte d'AzurMarseilleFrance
| | | |
Collapse
|
3
|
Lacour W, Adjili S, Blaising J, Favier A, Monier K, Mezhoud S, Ladavière C, Place C, Pécheur EI, Charreyre MT. Far-Red Fluorescent Lipid-Polymer Probes for an Efficient Labeling of Enveloped Viruses. Adv Healthc Mater 2016; 5:2032-44. [PMID: 27113918 PMCID: PMC7159338 DOI: 10.1002/adhm.201600091] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 02/25/2016] [Indexed: 12/13/2022]
Abstract
Far-red emitting fluorescent lipid probes are desirable to label enveloped viruses, for their efficient tracking by optical microscopy inside autofluorescent cells. Most used probes are rapidly released from membranes, leading to fluorescence signal decay and loss of contrast. Here, water-soluble lipid-polymer probes are synthesized harboring hydrophilic or hydrophobic far-red emitting dyes, and exhibiting enhanced brightness. They efficiently label Hepatitis C Virus pseudotyped particles (HCVpp), more stably and reproducibly than commercial probes, and a strong fluorescence signal is observed with a high contrast. Labeling with such probes do not alter virion morphology, integrity, nor infectivity. Finally, it is shown by fluorescence microscopy that these probes enable efficient tracking of labeled HCVpp inside hepatocarcinoma cells used as model hepatocytes, in spite of their autofluorescence up to 700 nm. These novel fluorescent lipid-polymer probes should therefore enable a better characterization of early stages of infection of autofluorescent cells by enveloped viruses.
Collapse
Affiliation(s)
- William Lacour
- Université Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie, F-69342, Lyon, France
- Université Lyon, INSA Lyon, Université Claude Bernard, CNRS, Laboratoire Ingénierie des Matériaux Polymères, F-69621, Villeurbanne, France
| | - Salim Adjili
- Université Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie, F-69342, Lyon, France
- Université Lyon, INSA Lyon, Université Claude Bernard, CNRS, Laboratoire Ingénierie des Matériaux Polymères, F-69621, Villeurbanne, France
| | - Julie Blaising
- Université Lyon, Univ Claude Bernard, INSERM U1052, CNRS 5286, Centre de Recherche en Cancérologie de Lyon (CRCL), F-69424, Lyon, France
| | - Arnaud Favier
- Université Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie, F-69342, Lyon, France
- Université Lyon, INSA Lyon, Université Claude Bernard, CNRS, Laboratoire Ingénierie des Matériaux Polymères, F-69621, Villeurbanne, France
| | - Karine Monier
- Université Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie, F-69342, Lyon, France
| | - Sarra Mezhoud
- Université Lyon, INSA Lyon, Université Claude Bernard, CNRS, Laboratoire Ingénierie des Matériaux Polymères, F-69621, Villeurbanne, France
| | - Catherine Ladavière
- Université Lyon, INSA Lyon, Université Claude Bernard, CNRS, Laboratoire Ingénierie des Matériaux Polymères, F-69621, Villeurbanne, France
| | - Christophe Place
- Université Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie, F-69342, Lyon, France
- Université Lyon, Ens de Lyon, Université Claude Bernard, CNRS, Laboratoire de Physique, F-69342, Lyon, France
| | - Eve-Isabelle Pécheur
- Université Lyon, Univ Claude Bernard, INSERM U1052, CNRS 5286, Centre de Recherche en Cancérologie de Lyon (CRCL), F-69424, Lyon, France
| | - Marie-Thérèse Charreyre
- Université Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie, F-69342, Lyon, France
- Université Lyon, INSA Lyon, Université Claude Bernard, CNRS, Laboratoire Ingénierie des Matériaux Polymères, F-69621, Villeurbanne, France
| |
Collapse
|